Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients

被引:23
|
作者
Onal, Cem [1 ]
Ozyigit, Gokhan [2 ]
Guler, Ozan Cem [1 ]
Hurmuz, Pervin [2 ]
Torun, Nese [3 ]
Tuncel, Murat [4 ]
Dolek, Yemliha [1 ]
Yedekci, Yagiz [2 ]
Oymak, Ezgi [5 ]
Tilki, Burak [2 ]
Akyol, Fadil [2 ]
机构
[1] Baskent Univ, Fac Med, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Radiat Oncol, TR-01120 Adana, Turkey
[2] Hacettepe Univ, Fac Med, Dept Radiat Oncol, Ankara, Turkey
[3] Baskent Univ, Fac Med, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Nucl Med, Adana, Turkey
[4] Hacettepe Univ, Fac Med, Dept Nucl Med, Ankara, Turkey
[5] Iskenderun Gelisim Hosp, Div Radiat Oncol, Antakya, Turkey
关键词
Prostate cancer; Radiotherapy; Prostate-specific membrane antigen; Positron emission tomography; Treatment volume; RADICAL PROSTATECTOMY; RADIATION ONCOLOGY; PATTERNS; FAILURE; ADENOCARCINOMA; IRRADIATION; THERAPY; PET/CT;
D O I
10.1016/j.radonc.2020.08.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the distribution of metastatic lymph nodes (LN) detected on Ga-68-PSMA-positron emission tomography/computed tomography (PET/CT) in treatment-naive prostate cancer (PC) patients and to analyze the LN coverage rates of the pelvic fields defined in the GETUG trial and RTOG guidelines and a pelvic field extending superiorly from the L4/L5 interspace. Materials and methods: Ga-68-PSMA-PET/CT images obtained at diagnosis of 138 PC patients were retro-spectively analyzed. The number and locations of Ga-68-PSMA-positive LNs were co-registered with one single-planning CT. The numbers, locations, and sizes of LNs located outside the three pelvic volumes were investigated for the entire cohort and for patients with LN metastasis in the pelvic area only. Results: A total of 441 PSMA-PET-positive LN metastases were identified. The most frequent metastatic LNs were internal iliac LNs (25.2%). Para-aortic and presacral LNs outside the three pelvic fields were present in 20 (14.5%) and 22 patients (15.9%), respectively. The LN coverage rates according to the GETUG trial, the RTOG guidelines, and the pelvic field extending superiorly from L4/L5 were 44.2%, 52.2%, and 71, respectively, in the entire cohort and 51.7%, 61 and 83.1%, respectively, in patients with only pelvic LN metastasis. The number of metastatic LNs was a predictive factor for LNs located outside the three pelvic fields. Conclusions: Extending the cranial margin of the pelvic field from L5/S1 to L4/L5 increases the accuracy of pelvic field irradiation in approximately 20% of patients, highlighting the importance of proximal common iliac irradiation, particularly in patients with multiple LN metastasis. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:222 / 227
页数:6
相关论文
共 50 条
  • [1] Comment on: Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients, by Onal C et al
    Goyal, Shikha
    Madan, Renu
    RADIOTHERAPY AND ONCOLOGY, 2021, 155 : E13 - E14
  • [2] Comment on: Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients, by Onal C et al response
    Onal, Cem
    RADIOTHERAPY AND ONCOLOGY, 2021, 155 : E15 - E15
  • [3] The Role of 68ga-PSMA-PET/CT in Pelvic FIELD Delineation in Prostate Cancer Patients with Pelvic Lymph Node Metastasis
    Onal, C.
    Hurmuz, P.
    Torun, N.
    Tuncel, M.
    Guler, O. C.
    Reyhan, M.
    Caglar, M.
    Ozyigit, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E299 - E299
  • [4] 68-Ga-PSMA-PET in the diagnosis of local recurrent disease after radiotherapy in patients with prostate cancer.
    Pfister, David
    Schmidt, Matthias
    Kohl, Tobias
    Porres-Knoblauch, Daniel
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] 68-Ga-PSMA-PET in lymph node staging in PSA recurrent prostate cancer-does the primary influence the result?
    Pfister, David
    Kohl, Tobias
    Porres-Knoblauch, Daniel
    Haidl, Friederike
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] 68-Ga-PSMA-PET in lymph node staging in PSA recurrent prostate cancer-does the Primary influence the result
    Pfister, D.
    Kohl, T.
    Porres, D.
    Haidl, F.
    Zugor, V.
    Heidenreich, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 101 - 101
  • [7] The Role of 68Ga-PSMA-PET/CT and Diffusion Weighted-MRI in Lymph Node Staging in Prostate Cancer Patients Treated with Definitive Radiotherapy
    Guler, O. C.
    Erbay, G.
    Torun, N.
    Onal, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E881 - E882
  • [8] 68Ga-PSMA ligand PET/CT guided radiotherapy planning of regional lymph node metastases in patients with prostate cancer recurrence
    Walacides, D.
    Derlin, T.
    Ross, T. L.
    Wester, H. -J.
    von Klot, C.
    Christiansen, H.
    Henkenberens, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S162 - S162
  • [9] Re: The role of 68Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
    Cihan, Yasemin Benderli
    INTERNATIONAL BRAZ J UROL, 2019, 45 (04): : 863 - 865
  • [10] Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis
    Polverari, Giulia
    Ceci, Francesco
    Calderoni, Letizia
    Cervati, Veronica
    Farolfi, Andrea
    Castellucci, Paolo
    Fanti, Stefano
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : 154 - 156